Insmed
Update in progressINSM (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Insmed Incorporated develops and commercializes therapies for serious and rare diseases in the United States, Europe, Japan, and beyond. It markets ARIKAYCE for refractory nontuberculous mycobacterial lung infections and is in phase 3 for MAC lung disease. It develops brensocatib for bronchiectasis, treprostinil palmitil inhalation for pulmonary hypertension, INS1201 gene therapy for Duchenne, INS1148 and INS1202 programs, plus preclinical gene therapy and AI research. Founded 1988, Bridgewater, NJ.
Company score
- Sentiment
- 0.33
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.27
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!